Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Viking Therapeutics, Inc. (NASDAQ: VKTX).

Full DD Report for VKTX

You must become a subscriber to view this report.


Recent News from (NASDAQ: VKTX)

Small Caps Are Rising, Biotechs Can't Be Far Behind
Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and...
Source: SeekingAlpha
Date: September, 05 2018 13:31
Welcome To The Formula - A Biotechnology Marketplace
(Editors' Note: This article is meant as an introduction for The Formula , a new Marketplace service by Clover Biotech Research.) The Formula Welcome To Seeking Alpha's Next Big Community! Your subscription and confidence in our service are important to me. While I cannot promise por...
Source: SeekingAlpha
Date: September, 04 2018 10:00
NASH Cirrhosis: The Real NASH Epidemic
Introduction Cirrhosis of the liver threatens the lives of millions of people, and other than a risky, expensive, and temporary transplant, it has no treatment. This marks cirrhosis among those diseases with the greatest unmet medical needs. Healthy liver, left, versus cirrhotic liver...
Source: SeekingAlpha
Date: August, 28 2018 14:19
Viking Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO , Aug. 28, 2018 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate in three up...
Source: PR Newswire
Date: August, 28 2018 07:30
Your Daily Pharma Scoop: Viking's Data Readout, Alpelisib Succeeds, Shire Receives Approval
Stocks in News : Viking Therapeutics up 7% ahead of mid-stage data readout on VK2809 Discussion: Share price of Viking Therapeutics ( VKTX ) has moved up 7% on average volume ahead of mid-stage data readout of its candidate VK2809. The anticipated trial data is indicated ...
Source: SeekingAlpha
Date: August, 25 2018 08:57

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-0710.119.7210.24859.551,795,513
2018-12-069.9810.0810.3299.761,977,494
2018-12-0511.0810.2611.3210.223,052,944
2018-12-0411.0810.3611.3210.342,133,066
2018-12-0311.5211.10511.6610.462,245,740

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-07191,922631,12530.4095Cover
2018-12-06134,431575,48223.3597Cover
2018-12-04308,941748,51341.2740Short
2018-12-03314,785849,69737.0467Short
2018-11-30154,321328,85846.9263Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VKTX.


About Viking Therapeutics, Inc. (NASDAQ: VKTX)

Logo for Viking Therapeutics, Inc. (NASDAQ: VKTX)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $265,182,758 - 05/18/2018
  • Issue and Outstanding: 50,898,802 - 02/28/2018

 


Recent Filings from (NASDAQ: VKTX)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 09 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 09 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: July, 19 2018
Simplified registration form
Filing Type: S-3Filing Source: edgar
Filing Date: July, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 12 2018
Registration of up to an additional 20% of securities for any offering registered on a S-3
Filing Type: S-3MEFFiling Source: edgar
Filing Date: June, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 07 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: June, 07 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: June, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 31 2018

 

 


Daily Technical Chart for (NASDAQ: VKTX)

Daily Technical Chart for (NASDAQ: VKTX)


Stay tuned for daily updates and more on (NASDAQ: VKTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: VKTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VKTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VKTX and does not buy, sell, or trade any shares of VKTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/